Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News GeneDx Holdings Equity Warrant Exp 22 July 2026 WGSWW

Financial Services Healthcare
GeneDx Holdings Corp. is a genomics company. The Company is focused on delivering personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The Company's segments are GeneDx inclusive of Legacy GeneDx and Legacy Sema4. The GeneDx segment primarily provides pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing... see more

Recent & Breaking News (NDAQ:WGSWW)

Sema4 to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

GlobeNewswire April 26, 2022

Sema4 Achieves HITRUST CSF Certification

GlobeNewswire April 6, 2022

Sema4 and Mount Sinai Use Integrative Network Analysis to Identify Potential New Lung Cancer Therapy

GlobeNewswire April 5, 2022

Sema4 Announces Nationwide Expansion of Disparity Study to Deliver Precision Oncology Care to Underserved Communities

GlobeNewswire March 16, 2022

Sema4 Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights

GlobeNewswire March 14, 2022

Sema4 Named to Fast Company's Annual List of the World's Most Innovative Companies for 2022

GlobeNewswire March 8, 2022

Sema4 to Report Fourth Quarter and Full Year 2021 Financial Results and Participate in Investor Conferences in March 2022

GlobeNewswire February 22, 2022

Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine

GlobeNewswire February 22, 2022

Sema4 to Participate at Two Upcoming Investor Conferences in February

GlobeNewswire February 3, 2022

Sema4 Announces Plans to Strengthen its Market Access Team to Drive Improved Commercial and Reimbursement Capabilities

GlobeNewswire February 1, 2022

Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

GlobeNewswire January 18, 2022

Sema4 Announces Preliminary Revenue for the Fourth Quarter and Fiscal Year 2021

GlobeNewswire January 10, 2022

Sema4 to Participate at the 40th Annual J.P. Morgan Healthcare Conference in January

GlobeNewswire January 3, 2022

Sema4 Reports Third Quarter 2021 Financial Results and Business Highlights

GlobeNewswire November 15, 2021

Sema4 and Mount Sinai use Machine Learning to Improve Postpartum Hemorrhage Risk Prediction

GlobeNewswire November 4, 2021

Sema4 to Participate at Three Upcoming Investor Conferences in November

GlobeNewswire November 3, 2021

Sema4 to Report Third Quarter 2021 Financial Results on Monday, November 15, 2021

GlobeNewswire October 19, 2021

Sema4 Appoints Computational Biology Expert Gustavo Stolovitzky as Chief Science Officer

GlobeNewswire September 13, 2021

Sema4 Launches Sema4 Elements(TM), a Portfolio of Data Science-Driven Products and Services to Support Reproductive and Generational Health

GlobeNewswire September 9, 2021

Sema4 to Participate at Two Upcoming Investor Conferences in September

GlobeNewswire August 30, 2021